Labcorp (LH) The 44th Annual William Blair Growth Stock Conference summary

Business overview and market trends

• Operates two synergistic business segments: diagnostic laboratories and biopharma laboratory services, leveraging global scale and advanced technology.

• Market trends such as aging populations, therapeutic advances, and rising healthcare costs drive demand for early detection, diagnosis, and precision medicine.

• Conducts over 650 million tests annually in 100 countries, with a database exceeding 45 billion data points.

• Maintains strong relationships with large pharma and biotech companies, and is active in scientific publications and major industry conferences.

• Holds about 10% share in a fragmented U.S. diagnostics market, with significant growth potential through consolidation.

Growth strategy and opportunities

• Near-term growth focuses on partnering with health systems and local/regional labs, and expanding specialty testing, including companion diagnostics.

• Long-term growth targets cell and gene therapy, consumer-centric testing, and leveraging the global lab network for targeted expansion.

• Recent launches include liquid biopsies in China and Europe, and new specialty tests in oncology, women's health, autoimmune, and neurology.

• Acquisitions of hospital and local labs have been accretive, with 15 deals since 2021, and integration expertise ensures rapid returns.

• Specialty areas are expected to grow 2-3x faster than the overall diagnostics market.

Recent developments and financial outlook

• Acquired select assets of Invitae for $239 million, expecting $275–$300 million revenue in year one; slightly dilutive in the first year, accretive thereafter.

• 2024 guidance: revenue growth of 5.6%, adjusted earnings up 10%, and free cash flow up 20%.

• Raised revenue guidance for diagnostics after a strong Q1, driven by acquisitions and underlying business strength.

• Long-term guidance (2023–2026): 5–8% revenue growth, 8.5–11.5% adjusted EPS growth, 100–150 bps margin expansion, and cash flow growth in line with earnings.